| Field | Specification |
|---|---|
| Target | |
| Alternative names | Protein CBFA2T1; Cyclin-D-related protein; Eight twenty one protein; Protein ETO; Protein MTG8; Zinc finger MYND domain-containing protein 2; RUNX1T1; AML1T1; CBFA2T1; CDR; ETO; MTG8; ZMYND2 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human RUNX1T1/ETO recombinant protein (Position: T335-D510). |
| Molecular weight | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets protein CBFA2T1 (gene RUNX1T1) in human, mouse and rat samples and is validated for ELISA, flow cytometry, immunoprecipitation, ICC/IF, IHC and Western blot. The predicted molecular weight is 67.6 kDa, and the supplier reports an observed band at about 67 kDa.
RUNX1T1 (also known as ETO or MTG8) is a transcriptional corepressor that binds DNA-binding transcription factors and recruits histone deacetylases and other repressors. It is best known as the partner in the RUNX1-RUNX1T1 (AML1-ETO) fusion found in acute myeloid leukemia, and it also restrains adipocyte differentiation.
| Target | Protein CBFA2T1 (gene RUNX1T1; UniProt Q06455, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 67.6 kDa |
| Observed MW | 67 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Mouse) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Immunoprecipitation | 0.5–2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human SH-SY5Y cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human mammary cancer tissue, mouse brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with a confirmed result (IP): SH-SY5Y cells.
Samples with a confirmed signal (flow cytometry): U2OS cells.
Immunogen
Recombinant human RUNX1T1/ETO fragment (Thr335–Asp510), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places protein CBFA2T1 in the nucleus. Tissue expression noted by UniProt (human): Most abundantly expressed in brain. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
